The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing
ConclusionNASM-PCR as a rapid genetic test holds promise for personalizing antiplatelet therapy in Asian CCS patients.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Angioplasty | Cardiology | Cardiovascular | Clopidogrel | Coronary Angioplasty | Genetics | Heart | Percutaneous Coronary Intervention | Plavix | Study